STOCKS TELEGRAPH

Tag: NUTX

  • 3 Stocks That Could Climb Higher: GH Research (GHRS), Nutex Health (NUTX), Cardiol Therapeutics (CRDL)

    3 Stocks That Could Climb Higher: GH Research (GHRS), Nutex Health (NUTX), Cardiol Therapeutics (CRDL)

    Across biotechnology and healthcare markets, investor sentiment is closely influenced by the pace and significance of clinical milestones achieved by emerging therapies. While short-term volatility is not uncommon, sustained market interest is often centered on solutions that address critical gaps in current standards of care.

    GH Research PLC (GHRS)

    GH Research PLC (NASDAQ: GHRS) opened trading on May 12, 2026, with great promise as it jumped 1.32% to $21.54. During the day, the stock rose to $21.75 and sank to $20.89. Taking a long-term approach, GHRS posted a 52-week range of $9.46-$24.66.

    The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 162.03%. Meanwhile, its Annual Earnings per share during the time were -162.03%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is -84.53%. This publicly-traded company’s shares outstanding now amount to $62.03 million, simultaneously with a float of $49.37 million. The organization now has a market capitalization of $1.48 billion.

    Nutex Health Inc (NUTX)

    Nutex Health Inc (NASDAQ: NUTX) started the day on May 12, 2026, with a price increase of 1.96% at $135.48. During the day, the stock rose to $135.53 and sank to $128.01. Taking a long-term approach, NUTX posted a 52-week range of $77.21-$193.07.

    Nevertheless, the stock’s Earnings Per Share (EPS) this year is 100.57%. This publicly-traded company’s shares outstanding now amount to $6.95 million, simultaneously with a float of $4.74 million. The organization now has a market capitalization of $932.28 million. Its Quick Ratio in the last reported quarter now stands at 3.12.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is advancing a broader cardiovascular growth strategy through the development of next-generation therapies aimed at large and underserved markets. By expanding beyond recurrent pericarditis, the company is positioning itself to participate in areas where inflammation and fibrosis remain important drivers of disease progression.

    Market Momentum

    As of May 12, 2026, CRDL closed at $1.35, up 1.12%, with trading volume of 353,515 shares compared to an average volume of 689,450 shares. The company currently maintains a market capitalization of $150.768M and a beta of 0.43, reflecting relatively moderate volatility compared to many small-cap biotech peers. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.39 suggests substantial upside potential tied to pipeline advancement and future clinical milestones.

    Pipeline Development: CRD-38

    Cardiol is developing CRD-38, a proprietary subcutaneous therapy designed to improve dosing convenience while expanding applicability into broader cardiovascular indications, including heart failure. The therapy is intended to target inflammation and fibrosis, two biological mechanisms strongly associated with declining cardiac function and progressive heart disease.

    Market Opportunity

    Heart failure represents one of the largest cardiovascular markets globally, affecting millions of patients and generating significant healthcare costs annually. Despite multiple treatment options already available, unmet need remains for therapies capable of directly addressing inflammatory and fibrotic pathways that contribute to disease progression.

    Outlook

    As CRD-38 advances toward future clinical development, the program could emerge as an important secondary value driver for Cardiol. Continued progress across the company’s pipeline may strengthen its long-term positioning within the cardiovascular biotechnology sector.

  • Nutex Health Inc. (NUTX) Sees Another Crazy Day After Recent Debut on Nasdaq. Why?

    On April 26, 2022, after recently making its public debut, the healthcare company, Nutex Health Inc. (NUTX) had another wild day. Ranging from over 73% gains in the regular session to nearly 11% in the after-hours, NUTX made huge strides. At a crazy volume of 75.43 million shares, the stock witnessed a high of $13.81 in the regular session. Following the after-hours gain, the stock was valued at $8.50 a share. Consequently, NUTX share prices gained 5.21% to $8.08.

    Source: NewsTrack

    While there is an SEC filing from the company, the huge rally seems to be on external factors rather than internal. However, the filing might have been a precursor to instigating investors’ interest once again in the stock.

    NUTX’s Latest SEC Filing

    The company’s latest SEC filing includes details of the directors’ appointment and agreements in connection to its business combination. Following its business combination, and appointment of independent directors, the company entered into a certain agreement with the directors. The agreements include a Board of Directors Agreement, a Proprietary Information Agreement, and an Indemnification Agreement.

    What’s the Fuss then?

    Given the contents of the SEC filing, it is highly unlikely to be the cause of the sudden uptick in NUTX on Tuesday.

    On April 4, the stock commenced trading on Nasdaq after a reverse merger was completed between Clinigence Holdings Inc. and Nutex Health Holdco LLC. The combination brought together a population health management company together with an independent operator of micro-hospitals and outpatient departments in the U.S. The combined company now has roughly 1500 employees across the country and over 800 partnered physicians.

    Since its debut on Nasdaq, the stock has traded in a wild range of $3.82-$52.80 a share. While volatility is expected after a merger, it seems the reverse nature of NUTX’s merger is extending its volatility. It seems external factors have investors viewing the stock as a speculative trading vehicle.

    What to Expect Now?

    Given the large and continued interest of investors in the stock, NUTX seems to have some more time before the soaring volatility dies down.

    On the other hand, the combined company has been a little too quiet since the merger and debut. While the company posed huge enthusiasm for the merger to have put it on the path to attractive growth opportunities, it’s probably going through many changes associated with the merger.

    Conclusion

    There still seems to be a little more time for NUTX to commence normal trading after the debut volatility subsides. However, the performance will now solely depend on what the company does next to ensure growth.